Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.
Hepatitis C medication Olysio was a star, but the company cautions competition is coming.
Phase III results showing improved lung function among cystic fibrosis patients using a combination of Kalydeco and lumacaftor means drugmaker Vertex is filing the two-part drug for FDA approval during the fourth quarter.
The Oregon Health Plan wants to keep hep. C medications Sovaldi and Olysio off its list of covered treatments.
Patients have to be high-risk or Baby Boomers for coverage.
Physicians tell Leerink most of their patients are receiving the drug. Rejections tend to be over off-label use.
A report indicates that Sovaldi's high price may hurt health-insurance investors.
Phase-II data show reduced hepatitis-C RNA levels among HIV-positive patients, the drugmaker shared at a medical meeting. Boehringer also released co-infection data.
Data presented at a conference yesterday suggest AbbVie's all-oral regimen may be more effective than Gilead's at curing the virus in certain patients, but will it confer an edge?